Merck KGaA, Darmstadt, Germany, Receives EU Commission Supplementary Statement of Objections in the Proceedings Concerning the Sigma-Aldrich Acquisition
Merck KGaA, Darmstadt, Germany, today received a Supplementary Statement of Objections (SSO) from the European Commission (EU Commission) in the ongoing proceedings concerning the Sigma-Aldrich acquisition, which was completed in 2015. In July 2017, Merck KGaA, Darmstadt, Germany, received a Statement of Objections from the European Commission. This relates to a packaging technology developed by Sigma-Aldrich prior to its acquisition by Merck KGaA, Darmstadt, Germany.
The SSO states that the allegations previously made against Merck KGaA, Darmstadt, Germany, will be dropped. The SSO retains allegations made against Sigma-Aldrich, which will be the object of the ongoing proceedings.
From the very beginning of the antitrust review proceeding, Merck KGaA, Darmstadt, Germany, has cooperated and engaged in a constructive dialogue with the European Commission.
Merck KGaA, Darmstadt, Germany, is confident that it will be possible to resolve the situation satisfactorily. Since this matter is still ongoing, Merck KGaA, Darmstadt, Germany, will not comment any further on it at this point in time.
All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group Website. In case you are a resident of the USA or Canada please go to www.emdgroup.com/subscribe to register for your online subscription of this service as our geo-targeting requires new links in the email. You may later change your selection or discontinue this service.
About Merck KGaA, Darmstadt, Germany
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials. Around 57,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2019, Merck KGaA, Darmstadt, Germany, generated sales of € 16.2 billion in 66 countries.
The company holds the global rights to the name and trademark “Merck” internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials. Since its founding 1668, scientific exploration and responsible entrepreneurship have been key to the company’s technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company.
Based on high demand expected to continue throughout the year and a very strong first quarter of 2021 with net sales of EUR 4.63 bn resulting in EBITDA pre of EUR 1.51 bn and EPS pre of EUR 2.18, ...